Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr

1^st half revenue from operations up 6%

Syngene International Limited today announced financial results for the second quarter and half year of FY26.

Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins)

H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins)

Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim.

Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing. We are maintaining our annual guidance for revenue for FY26.

This quarter, we won our first contract for a global phase III clinical trial from a U.S.-based biotech company which will recruit patients across clinical sites in U.S. and India. In line with our plans to strengthen our capabilities in new modalities, we are building a new GMP bioconjugation suite in the biologics facility in Bengaluru. This will enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), placing us amongst a select group of CRDMOs with full-service ADC capabilities.

From a broader perspective, the U.S. biotech funding environment is showing early signs of improvement. We continue to monitor trends and maintain agile strategies to adapt quickly as the funding environment evolves.”

Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “Our strong balance sheet and net cash position provide the financial flexibility to invest in key strategic priorities to support our growth. The Company is investing in dedicated facilities for peptides and ADCs augmenting our platforms in the fast-growing new biologics modalities.

With diversified service offerings across the value chain and available biologics manufacturing capacity, we are well-placed to capitalize on opportunities that will drive medium to long-term growth.

We are maintaining our EBITDA and PAT margin guidance for the full year.”

Key Business Highlights:

The Company secured its first global phase III clinical trial from a U.S.-based biotech company. The trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene’s growing capabilities in the global clinical trials market.

Syngene has also expanded its clinical trials footprint to Australia, New Zealand, the UK, Sri Lanka, and Eastern Europe, strengthening global trial execution capabilities through strategic partnerships with well-established CROs in these regions.

Syngene will expand its biologics facility in Bengaluru with a GMP bioconjugation suite to provide fully integrated, end-to-end manufacturing of ADCs. The suite will accelerate development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site and complement Syngene’s existing commercial capabilities in payload and linker manufacturing.

Progress at the Bayview biologics manufacturing facility in the U.S. remains on track, with revalidation, integration, and staff recruitment advancing towards operationalization in the second half of the year.

The sustainability assessment of Syngene’s laboratories, conducted by US sustainability certification expert, My Green Lab (MGL), earned the highest level ‘Green Certification’ with a score exceeding 94%. Further, Syngene strengthened its position as a global sustainability leader, with its EcoVadis 2025 score rising to 74/100, up from 66 last year. This places the company in the 91st percentile, ranking it among the top companies worldwide for sustainability practices.

Earnings Call: Syngene will host an investor call at 2 pm IST on November 6, 2025, where the senior management will discuss the Company’s performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279 / +91 22 7115 8180 . Participants can also join the call via this webcast link. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available until 13^th November 2025, on +91 22 71945757, Playback ID: 31280 We will aim to post the transcript of the conference call on the company website within seven working days of the investor conference call.